Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has conducted a study examining the effectiveness of the “Medical Patient Review continuous quality improvement” (MPR-CQI) program in 20 countries of the region Europe, Middle East and Africa (EMEA). The study has demonstrated, by means of mediation analysis, that improvements in medical key performance indicators (KPIs), occurring after the MPR-CQI program implementation, was associated with a significant reduction in mortality risk of about 30 percent in study participants. 

For the development of the MPR-CQI program, the company used therapy data from more than 70,000 patients treated in Fresenius Medical Care’s EMEA NephroCare network to define, monitor and improve 10 KPIs – intermediate clinical endpoints – including hemoglobin, hydration status, hemodynamic status and infusion volume. The Medical Patient Review’s monthly review circles and evaluations of patients’ health indicators allow physicians to identify, prioritize and address patient’s medical needs. 

“Delivering the highest quality care for people living with kidney disease is central to our mission, and data-driven insights are vital for ongoing clinical care improvement and innovation,” said Franklin W. Maddux, MD, Global Chief Medical Officer of Fresenius Medical Care. “The breadth and depth of our company’s clinical data, combined with our efforts in digital innovation and connected health, are generating a compelling evolution of clinical results.” 

The quality performance of Fresenius Medical Care’s clinical governance strategy has been evaluated in an historical cohort study based on the company's own EuCliD database in the EMEA region. The company has published the study results in Nephrology, Dialysis & Transplantation, the official journal of the European Renal Association/European Dialysis and Transplant Association, to make them publicly available to the professional community and support further improvements in care worldwide: https://doi.org/10.1093/ndt/gfab160

The Medical Patient Review continuous quality improvement program is based on EuCliD data – Fresenius Medical Care’s digital patient care system- and enables the company to define evaluation processes involving medical and nursing experts. It also enables a detailed analysis of patients that allows a better understanding of medical needs, while providing intensive experiences from correlating improvements in medical and economic efficiency results – to deliver feedback focused on effective and efficient care. Through its digital patient care system, Fresenius Medical Care is planning to also enable third-party clients to benefit from the MPR. 

As part of its 2025 growth strategy, Fresenius Medical Care is using digital technologies and artificial intelligence (AI) to develop new forms of kidney therapy. Physicians in more than 100 clinics in the company’s network can already use an AI-based algorithm that can help to improve renal anemia management while reducing drug-related costs. Fresenius Medical Care is planning to enrich the Medical Patient Review process by the MPR Advanced Benchmarking System which is based on an ensemble of 22 AI-based models that are designed to help detect best clinical practices, pinpoint high-performing centers beyond case-mix differences, discover emerging medical needs and set realistic margins of improvement for each intermediate clinical endpoint in all clinics.

The MPR Advanced Benchmarking System will be piloted starting this fall in NephroCare clinics in one EMEA country. Additional AI-based products for the management of non-dialysis dependent chronic kidney disease, vascular access care, home dialysis therapies and intradialytic complications are now being developed.
 

Infusion therapy is the administration of medication intraveniously through a needle or catheter. Among the essential products are infusion solutions, medical devices, blood volume replacement solutions, and medical products such as rinsing solutions as well as intravenously-administered drugs.

Infusion solutions, for example, comprise electrolyte and glucose solutions as well as concentrated carbohydrate solutions, infusion solutions containing electrolytes and substrate solutions for drugs. Volume replacement solutions based on hydroxyethyl starch (HES) are used to increase plasma volume.

I.V. Drugs

Intravenous administration of drugs is indispensable today. A patient is administered drugs intravenously, meaning directly into a vein. This type of administration is used in cases of emergency, since the drug this way reaches the entire human body directly through the bloodstream and can be effective within a few seconds. Drugs are also administered intravenously in intensive care and during surgeries. Physicians decide to administer drugs via the vein particularly when patients are no longer able to take drugs orally or if the digestive tract no longer functions properly.

Fresenius Kabi offers a wide range of generic intravenously administered drugs. Primarily severely ill patients in hospitals are treated with these drugs – for example at emergency wards and intensive care units. Analgesics and anesthetics as well as antibiotics and antiinfectants are among these drugs.

The interactive tool allows you to analyze and graph the Fresenius SE & Co. KGaA share price. 

   

 

Fill out the fields and click "Show data". The Total Return Calculator will provide you with the current value of your Fresenius shares and the return. Moreover, the Calculator shows the share price performance during the selected period.

Members of the Supervisory Board of Fresenius SE & Co. KGaA

Committees of the Supervisory Board of Fresenius SE & Co. KGaA

Additional information on the Supervisory Board of Fresenius SE & Co. KGaA

Members of the Supervisory Board of Fresenius Management SE

For blood donation and component processing, Fresenius Kabi offers medical devices. These include cell separators (apheresis systems), autotransfusion devices, blood bag and filter systems as well as related blood processing equipment. Component processing consists of the separation and collection of certain blood cells.

Blood Cell Separator

The Fresenius cell separator has three areas of application:

• Donate blood cells: obtaining cells from the blood of a donor for transfusion, for example for treating coagulation dysfunctions or leukemia patients
• Remove cancer cells: removing diseased cells or blood plasma from the blood of a patient with leukemia or an autoimmune disease, i. e., in patients with disorders where the body produces defense substances against its own cells
• Collect a patient’s cells: collecting cells from a patient's own blood for re-infusion, for example prior to operation.

Blood bag systems

Blood bag systems are the foundation for worldwide blood supply by "classical" blood donation. More than 90 percent of all blood donations are processed in these systems that consist of up to six different bags with variable functions.

A combination of bags with venous cannulae and integrated needle protection, pre-donation sampling pouches and different filtration devices form the basis for highly professional whole blood collection systems. They allow producing different blood component preparations according to national and international standards. Blood donation and processing with these systems is supplemented by other devices such as automated scales and blood separators, sterile docking systems and sealers to name a few.

Comprehensive patient care begins with prevention. Fresenius Helios' occupational healthcare centers offer a wide range of workplace prevention services. In addition, the Helios Prevention Center (HPC) of Fresenius Helios offers programs for individual prevention and company health management in the form of checkups and health coaching at numerous locations around Germany.
 

Occupational Healthcare

The aim of effective occupational healthcare is to maintain and promote health, prevent harmful influences resulting from working life, detect illnesses and damage to health at an early stage, as well as reintegrate employees into the workplace after a longer period of absence due to illness.

In Germany, Helios offers fully comprehensive occupational medical care with a fixed, permanent contact person at 17 occupational healthcare centers. This covers everything from legally required examinations, health protection and promotion to risk assessments and recommendations for optimal workplace design.

Spain's leading occupational risk prevention companies Fraterprevención, MC Prevención, Premap and Unipresalud complement the Quirónsalud network, with more than 150 centers throughout Spain and a presence in Latin America and the Middle East.

 

Helios Prevention Center (HPC)

A check-up at the Helios Prevention Center provides an accurate picture of one's own state of health. Our participants at one of our six locations benefit from short waiting times, short distances and holistic lifestyle advice.

The HPC qualifies participants to handle health issues with confidence and enables them to achieve a performance grade that can function as a model. Health conscious and competent leadership can act as a beacon to bind together and motivate employees. HPC views itself as a partner to companies that want to actively promote the health of their employees. From a one-day checkup at a Helios clinic to health workshops lasting several days at beautifully situated resorts – our modular program combines Helios quality with the ambience of exclusive hotels. Studies show occupational healthcare measures generate outstanding cost-benefit ratios.

Fresenius Vamed is a leading global provider of services for hospitals and other healthcare facilities. Its portfolio ranges from project development and planning to the total operational management of healthcare facilities and providing services to patients. The services are aimed at various areas of healthcare, ranging from prevention to acute care, rehabilitation, and nursing.

Headquartered in Vienna, Austria, Fresenius Vamed has successfully completed more than 1,000 healthcare projects in 101 countries on five continents since the company’s founding in 1982.

VAMED Value Chain

Project business:

• Project development
• Planning
• Project management and construction
   

Service business:

• Services (technical, commercial, infrastructural)
• Operational management (technical Management, total operational management)
   

Vamed belongs to Fresenius SE & Co. KGaA healthcare group with a stake of about 77 percent and is one of the two Investment Companies of Fresenius. 

Helios is part of the Fresenius healthcare group and is Europe's leading private health care provider, with 128,000 employees. Fresenius Helios includes the Helios Group in Germany and Quirónsalud in Spain and Latin America. Every year about 26 million patients choose Helios for their medical treatment. In 2024, the company’s sales totaled more than €12.7 billion.

Helios Germany operates more than 80 hospitals, about 220 outpatient care centers with about 570 accredited doctor's licenses, six prevention centers and 27 occupational medicine centers. Helios treats approximately 5.5 million patients annually, of whom 4 million are outpatients. Since its beginnings, Helios has focused on measurable, high medical quality as well as data transparency and is better than the German average in more than 90 per cent of the quality targets. With about 78,000 employees, Helios generated sales of €7.7 billion in 2024. Helios Germany is headquartered in Berlin.

Quirónsalud operates 57 hospitals, including seven in Latin America, around 130 outpatient centers and more than 300 occupational risk prevention centers, and treats approximately 20 million patients annually, of whom 19 million are outpatients. Quirónsalud has about 50,000 employees and generated sales of more than €5 billion in 2024.